The first coronavirus vaccine to enter human trials has returned “positive” results, its manufacturer said Monday
Moderna Therapeutics saw “positive” results from early vaccine tests. Photo: Aflo/Shutterstock . Moderna, the Boston-based biotech firm that began testing the vaccine in March, announced that eight healthy patients, who each received two doses of the vaccine, developed antibodies that fight the virus.
In Moderna’s Phase 1 trial, half of the eight patients received two doses of 25 micrograms, and the other half received two doses of 100 micrograms. Those who received the smaller does showed levels of antibodies similar to those in people who have recovered from COVID-19. For those who received the higher dose, antibody levels “significantly exceeded” those in recovered patients.
In an interview with Stat News, Zaks said there is a balance to strike between an effective dosage level and using as little vaccine as needed, allowing for maximum production. “The sense is, at the end of the day, we’re going to narrow it down on somewhere between 25 and 100,” he said. “It’s going to be really hard math for us.”
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Early Results from Coronavirus Vaccine Trial Show Promising Immune ResponseHospital’s First Coronavirus Patient Discharged After Two Months\n
Weiterlesen »
Moderna reports 'positive' data on early-stage coronavirus vaccine trial, shares surge 39%Moderna's early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, sending the company's shares surging.
Weiterlesen »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Moderna reports positive data on early-stage coronavirus vaccine trial, shares surgeModerna said its early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all participants, sending its shares surging.
Weiterlesen »
Dow soars more than 700 points, after favorable, early results for coronavirus vaccine candidateU.S. stocks climbed at the start of Monday after drugmaker Moderna announces positive, early results from its first human trial of its experimental Covid-19...
Weiterlesen »
Moderna's COVID-19 vaccine shows early promise; shares soarEarly data from Moderna Inc's COVID-19 vaccine, the first to be tested in the United States, showed that it produced protective antibodies in a small group of healthy volunteers, the company said on Monday.
Weiterlesen »